HH
Novarock biotherapeutics
A monoclonal antibody blocking IL23p19 from binding its receptor in chronic skin inflammation.
Sponsored researchIn developmentSupplier
Get the Discover digest
Receive a weekly email digest of the latest immunology and immune-mediated disease solutions added by the network.Discover innovations in immunology and immune-mediated disease
Get the Discover digest
Receive a weekly email digest of the latest immunology and immune-mediated disease solutions added by the network.Browse 443 solutions in immunology & immune-mediated disease on the Halo network
Updated Sept 30, 2026
Immunology covers the antibodies, cell therapies and small molecules that turn an immune response up, down or sideways. On Halo, the solutions cover antibodies and named targets, neuroinflammation, tumor immunology, and tolerance and immunosuppression. Sign up to search the full network and post your specific need.
Antibodies and named targets
HH
AS
SignaBlok, Inc.
Ligand-independent TREM-1 blockade, with safety data behind a first-in-class candidate.
Co-developmentIn developmentStartup
CW
Montana State University
Epitope-mapped mouse monoclonals against human neutrophil receptors and inflammation proteins.
LicensingIn developmentUniversity
Human scFv phage display libraries offered for new antibody discovery.
Sponsored researchIn developmentStartup
Neuroinflammation
PA
CUNY Graduate School and University Center
Modulates the integrated stress response in specific brain cell types and not the whole tissue.
Sponsored researchIn developmentUniversity
AK
University of Copenhagen
Whole-brain spatial transcriptomics used to map distinct microglial activation states.
Sponsored researchIn developmentUniversity
Investigates brain insulin receptor signalling as a control point for neuroinflammation in Alzheimer's.
Sponsored researchIn developmentUniversity
MO
University of Lincoln
Bolaamphiphile vesicles that cross the blood-brain barrier to reach microglia.
In developmentUniversity
Tumor immunology
DG
A CpG formulation that stays in the tissue it is injected into, for localized tumor immunostimulation.
In developmentStartup
CG
Riptide Bioscience Inc.
A CD206 agonist aimed at tumor-associated macrophages, reversing immune suppression.
In developmentSupplier
NS
University of California, San Diego
Cowpea mosaic virus used intratumorally to provoke a host immune response.
In developmentUniversity
KC
Nationwide Children's Hospital
Oncolytic HSV driving tumor antigen expression to raise T and B cell responses.
In developmentUniversity
You're viewing a preview of immunology and immune-mediated disease solutions on Halo.
Sign up free to search the full network and post your specific need.
Already have an account?
Who is working on immunology & immune-mediated disease
Organizations in immunology & immune-mediated disease
Universities, startups, and suppliers with solutions in immunology and immune-mediated disease.
Immunology and immune-mediated disease companies
Innovators in immunology & immune-mediated disease
Researchers and inventors advancing immunology and immune-mediated disease.
Immunology and immune-mediated disease expertsAbout immunology & immune-mediated disease
Immunology on Halo splits three ways: antibodies against named inflammatory targets, a substantial neuroinflammation cluster, and work on tolerance for autoimmune disease. On Halo it spans six groups, including antibodies and named targets, neuroinflammation, and tumor immunology.
Stage of development. Work on immunology & immune-mediated disease on Halo comes mostly from university programs. 84% are past proof of concept (TRL 4 or higher). Co-development and sponsored research are the usual partnering routes, and about 53% of the solutions that state terms offer licensing.
Three trends in immunology and immune-mediated disease on Halo
The brain as an immune organ. Five solutions treat neurological disease as inflammation. One maps microglial activation states across the whole brain, another modulates the integrated stress response in named cell types, and a third builds vesicles that cross the blood-brain barrier to reach microglia. The target is the immune cell, not the neuron.
Tolerance and not suppression. Several programs try to teach the immune system in place of blunting it: engineered exosomes displaying inhibitory molecules, nanoparticles that shift metabolite ratios inside immune cells, and an AAV platform making anti-inflammatory protein only where it is needed. All three avoid systemic immunosuppression.
Keeping the stimulus local. Tumor immunology is preoccupied with staying put. A CpG formulation is built to be retained in the tissue it is injected into, microneedles modulate the microenvironment directly, and one delivery platform mimics T cell trafficking to reach the lymph node. Where the immune signal lands is the whole design problem.
424organizations
443solutions listed
61%from university labs
84%past proof of concept
Frequently asked questions
What is immunology and immune-mediated disease?
Immunology covers the antibodies, cell therapies and small molecules that raise, lower or redirect an immune response. It spans antibodies against named inflammatory targets, tolerance induction for autoimmune disease, neuroinflammation, and the safety assessment that tells a developer whether a candidate will provoke a dangerous reaction. Pharmaceutical and biotechnology developers are the buyers. On Halo the work leans toward antibodies and named targets, neuroinflammation, and tumor immunology.
What are examples of immunology and immune-mediated disease?
Four examples of immunology and immune-mediated disease solutions on Halo include:
- A monoclonal antibody blocking IL23p19 from binding its receptor in chronic skin inflammation. (Novarock biotherapeutics)
- Modulates the integrated stress response in specific brain cell types and not the whole tissue. (CUNY Graduate School and University Center)
- A CpG formulation that stays in the tissue it is injected into, for localized tumor immunostimulation. (Kinimmune, Inc.)
- Poly(alpha-ketoglutarate) nanoparticles shifting metabolite ratios inside immune cells toward suppression. (Case Western Reserve University)
What are the latest immunology and immune-mediated disease innovations?
Over the past 90 days, researchers and innovators on Halo have added these immunology and immune-mediated disease solutions:
Which companies and suppliers are developing immunology and immune-mediated disease?
There are 424 organizations with immunology and immune-mediated disease solutions on Halo, 86 of them universities and research institutions. Among them are Novarock biotherapeutics, SignaBlok, Inc., and Montana State University. Most offer co-development or sponsored research. Sign up to see every organization working in the area and to send them your specific need.
How do I find immunology and immune-mediated disease research partners?
Browsing immunology and immune-mediated disease solutions on Halo is free. Sign up to search the full network and save the ones you want. Post your specific need to get exact matches. Organizations reply directly on the platform.
Related medicine research areas
Confirm digest type